Camurus Past Earnings Performance
Past criteria checks 6/6
Camurus has been growing earnings at an average annual rate of 67.2%, while the Pharmaceuticals industry saw earnings declining at 0.9% annually. Revenues have been growing at an average rate of 54.1% per year. Camurus's return on equity is 28.9%, and it has net margins of 25.1%.
Key information
67.2%
Earnings growth rate
68.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 14.1% |
| Revenue growth rate | 54.1% |
| Return on equity | 28.9% |
| Net Margin | 25.1% |
| Next Earnings Update | 08 May 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Camurus makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 1,717 | 431 | 424 | 638 |
| 30 Sep 23 | 1,610 | 460 | 383 | 543 |
| 30 Jun 23 | 1,468 | 408 | 356 | 502 |
| 31 Mar 23 | 1,020 | 115 | 330 | 457 |
| 31 Dec 22 | 956 | 56 | 309 | 474 |
| 30 Sep 22 | 871 | 28 | 289 | 445 |
| 30 Jun 22 | 784 | -13 | 268 | 422 |
| 31 Mar 22 | 695 | -69 | 249 | 423 |
| 31 Dec 21 | 601 | -90 | 240 | 389 |
| 30 Sep 21 | 523 | -142 | 275 | 355 |
| 30 Jun 21 | 470 | -156 | 285 | 319 |
| 31 Mar 21 | 413 | -128 | 275 | 252 |
| 31 Dec 20 | 336 | -167 | 269 | 239 |
| 30 Sep 20 | 265 | -174 | 214 | 229 |
| 30 Jun 20 | 205 | -216 | 197 | 246 |
| 31 Mar 20 | 136 | -284 | 198 | 263 |
| 31 Dec 19 | 106 | -290 | 194 | 249 |
| 30 Sep 19 | 78 | -305 | 192 | 248 |
| 30 Jun 19 | 58 | -286 | 168 | 235 |
| 31 Mar 19 | 53 | -266 | 145 | 225 |
| 31 Dec 18 | 49 | -235 | 123 | 208 |
| 30 Sep 18 | 47 | -200 | 100 | 194 |
| 30 Jun 18 | 40 | -208 | 93 | 205 |
| 31 Mar 18 | 52 | -187 | 80 | 206 |
| 31 Dec 17 | 54 | -191 | 72 | 223 |
| 30 Sep 17 | 86 | -166 | 64 | 234 |
| 30 Jun 17 | 104 | -127 | 55 | 209 |
| 31 Mar 17 | 111 | -102 | 49 | 191 |
| 31 Dec 16 | 114 | -81 | 43 | 172 |
| 30 Sep 16 | 113 | -85 | 29 | 154 |
| 30 Jun 16 | 120 | -95 | 26 | 156 |
| 31 Mar 16 | 116 | -189 | 31 | 151 |
| 31 Dec 15 | 155 | -160 | 31 | 153 |
| 30 Sep 15 | 263 | -53 | 42 | 153 |
| 31 Dec 14 | 208 | 48 | 34 | 114 |
| 31 Dec 13 | 198 | 99 | 22 | 53 |
Quality Earnings: 0RD1 has high quality earnings.
Growing Profit Margin: 0RD1's current net profit margins (25.1%) are higher than last year (5.8%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 0RD1 has become profitable over the past 5 years, growing earnings by 67.2% per year.
Accelerating Growth: 0RD1's earnings growth over the past year (676.6%) exceeds its 5-year average (67.2% per year).
Earnings vs Industry: 0RD1 earnings growth over the past year (676.6%) exceeded the Pharmaceuticals industry 2.6%.
Return on Equity
High ROE: 0RD1's Return on Equity (28.9%) is considered high.